Cenderitide

Cenderitide was engineered at the Mayo Clinic by grafting the 15-residue C-terminal tail of Dendroaspis natriuretic peptide, from green mamba venom, onto the 22-residue ring structure of human C-type natriuretic peptide. The CNP portion drives NPR-B activation, which is enriched in fibroblasts and mediates antifibrotic and antiproliferative signalling; the DNP tail restores NPR-A activity for natriuresis and glomerular filtration support. In proof-of-concept human work it raised plasma and urinary cGMP, suppressed aldosterone and preserved glomerular filtration rate without a clinically significant fall in blood pressure - the specific failure mode that sank nesiritide. Development has focused on subcutaneous continuous delivery via a wearable pump and on drug-eluting stent and cardiac patch formats.

Targets: Natriuretic peptide receptor B (NPR-B / guanylyl cyclase B), Natriuretic peptide receptor A (NPR-A), cGMP pathway

• · Trial infusion rates were in the low nanograms per kilogram per minute range and were dose-escalated to the limit of blood pressure tolerance. There is no established dose outside a clinical trial and no legitimate consumer protocol.

Work out your exact syringe units →

• commonHypotension— Milder than with BNP-based agents by design, but still the dose-limiting effect at higher infusion rates.
• commonHeadache
• commonInjection-site or pump-site reaction— Reported with the continuous subcutaneous delivery format.
• commonDizziness

• Hypotension or cardiogenic shock, as with every natriuretic peptide.
• Preload-dependent states such as severe valvular stenosis or tamponade.
• Any use outside a clinical trial, since no safety-qualified product exists.

• redundantnesiritide — Overlapping NPR-A activation with additive hypotension.
• cautionsacubitril-valsartan — Neprilysin inhibition would raise cenderitide exposure and amplify vasodilatation.
• cautionACE inhibitors — Additive blood pressure lowering.

• · Blood pressure, which is the dose-limiting variable.
• · Serum creatinine and estimated GFR.
• · Plasma or urinary cGMP as the pharmacodynamic marker used in trials.

Investigational only. Not approved in any jurisdiction; no legitimate route of supply outside a clinical trial.

• Lee et al. 2009, CD-NP proof-of-concept study in chronic heart failure (trial)
• Ichiki, Burnett et al., cenderitide as a multivalent designer agonist of particulate guanylyl cyclase receptors (EHJ-CVP review) (review)

Cenderitide is a deliberate piece of protein engineering rather than a natural hormone. Native CNP signals mainly through NPR-B, which sits on vascular smooth muscle and fibroblasts and produces venodilation and antifibrotic effects but very little natriuresis and very little arterial hypotension. ANP and BNP signal through NPR-A, which drives the renal and natriuretic effects but also the arterial hypotension that limited nesiritide and carperitide. Cenderitide bolts the C-terminal 15 residues of Dendroaspis natriuretic peptide, a green mamba venom peptide with potent NPR-A activity, onto CNP, producing a single molecule that activates both receptors. The intended clinical shape is the one heart failure actually needs: raise cGMP in the kidney enough to preserve glomerular filtration and suppress aldosterone, raise it in the venous system enough to unload the ventricle, and do it without dropping arterial pressure the way pure NPR-A agonists do. The first-in-human study in healthy volunteers confirmed cGMP activation, natriuresis and aldosterone suppression without excessive hypotension, and the small heart failure studies that followed showed the same pattern with preserved GFR. That is a genuinely interesting result. It is also, twenty years on, still where the evidence stops.

The honest failure mode for cenderitide is that it never happened. Development has been slow for well over a decade, the largest human study on the registry enrolled 58 patients, and there are no efficacy outcome data at all. Anything sold as cenderitide outside a clinical trial is an unregulated research chemical of unverified identity, and there is no published human dose, no established route outside a continuous pump, and no safety database beyond a few dozen closely monitored patients. The pharmacology is elegant. The clinical evidence is a rounding error.

• NPR-B / particulate guanylyl cyclase B

  The CNP portion drives this. Venodilation and antifibrotic signalling in vascular smooth muscle and cardiac fibroblasts, with minimal arterial pressure drop.

• NPR-A / particulate guanylyl cyclase A

  The DNP tail recruits this. Adds natriuresis, glomerular filtration support and aldosterone suppression.

• NPR-C clearance receptor

  Clearance route shared with the rest of the family.

• CD-NP first-in-human study in healthy subjects (NCT00482937) Phase 1 · n=22 · 2009

  Safety and pharmacodynamics of the chimeric peptide. Demonstrated cGMP activation, natriuresis and aldosterone suppression without excessive hypotension.

• Phase 2 study of CD-NP in acute decompensated heart failure (NCT00839007) Phase 2 · n=77

  Safety and efficacy of CD-NP in acute decompensated heart failure. Completed; results have not driven further development.

• PK/PD study of subcutaneous cenderitide infusion in chronic heart failure (NCT01316432) Phase 1 · n=58

  Pharmacokinetics and pharmacodynamics of continuous subcutaneous cenderitide infusion in chronic heart failure. The largest human cenderitide study on the registry.

• Cenderitide in stable LVAD patients (NCT01750905) Phase 1 · n=14

  Safety of chimeric natriuretic peptide in stable left ventricular assist device patients.

cGMP rises within the first hour of infusion in the human studies, with natriuresis and aldosterone suppression over the same timeframe. Effects stop with the infusion; the molecule is short-lived even with the DNP tail.

Everything that raises cGMP or lowers blood pressure adds to cenderitide: nitrates, PDE5 inhibitors, sacubitril/valsartan (which also slows the drug's own degradation by inhibiting neprilysin), ACE inhibitors and ARBs. In the heart failure setting these are all background therapy, which is precisely why avoiding additional hypotension was the design brief. There is no rational stack for a compound with no established dose.

Against nesiritide and carperitide, both pure NPR-A agonists, cenderitide's claim is renal preservation without hypotension, and the small human datasets are consistent with that claim. Against sacubitril/valsartan, which raises endogenous natriuretic peptides by blocking their degradation and has hard outcome data, cenderitide is a far more targeted tool with none of the evidence. That comparison is the reason the field moved on.

No approved product and no legitimate market price. Research-chemical listings exist but their identity and purity are unverified.

• ?I could not verify the full 37-residue sequence letter by letter, only the design description (CNP-22 plus the 15-residue DNP C-terminus), so the sequence object is marked unverified with no one-letter string.
• ?No human half-life, clearance, volume of distribution or bioavailability figures were resolvable; all are null.
• ?Publication status and results of the phase 2 acute heart failure study (NCT00839007) were confirmed only as completed on the trial registry, not as a published outcome paper.
• ?Molecular weight is not given in the Core record and I did not find a reliable published value.

• Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr, J Clin Pharmacol, 2009 · PMID 19395584

  The first-in-human data and the clearest statement of the design rationale.

• Natriuretic peptide based therapeutics for heart failure: cenderitide, a novel first-in-class designer natriuretic peptide Ichiki T, Burnett JC Jr, Int J Cardiol, 2019 · PMID 29941213

  Review by the group that built the molecule; the best single summary of where it stands.

• Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions Lee CY, Huntley BK, McCormick DJ, Ichiki T, Sangaralingham SJ, Burnett JC Jr, Eur Heart J Cardiovasc Pharmacother, 2016 · PMID 27340557

  Why the specific CNP plus DNP-tail architecture, and what happens if you change it.

• Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation Dickey DM, Potter LR, J Mol Cell Cardiol, 2011 · PMID 21459096

  The proteolysis-resistance claim, tested directly.

• CD-NP, a chimeric natriuretic peptide for the treatment of heart failure Rose RA, Curr Opin Investig Drugs, 2010 · PMID 20178049

  Independent review of the concept.